Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Express Scripts
Fuji
Argus Health
Baxter
Johnson and Johnson
Medtronic
McKinsey

Generated: July 16, 2018

DrugPatentWatch Database Preview

Lopinavir; ritonavir - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for lopinavir; ritonavir and what is the scope of lopinavir; ritonavir freedom to operate?

Lopinavir; ritonavir
is the generic ingredient in two branded drugs marketed by Abbvie and Lannett Co Inc, and is included in four NDAs. There are sixteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lopinavir; ritonavir has fifty-one patent family members in thirty-one countries.

There are thirteen drug master file entries for lopinavir; ritonavir. Nine suppliers are listed for this compound. There are six tentative approvals for this compound.
Synonyms for lopinavir; ritonavir
(2S)-N-[(1S,3S,4S)-1-benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide; thiazol-5-ylmethyl N-[(1S,2S,4S)-1-benzyl-2-hydroxy-4-[[(2S)-2-[[(2-isopropy
369372-47-4
ABT-378 & ABT-538
Aluvia(TM)
AM023031
D02498
DTXSID30190428
Kaletra(TM)
Lopinavir - ritonavir mixt
Lopinavir / Ritonavir
Lopinavir & Norvir
Lopinavir & Ritonavir
Lopinavir mixture with ritonavir
Lopinavir-Ritonavir mixt
Lopinavir/Ritonavir
LPV / RTV
LPV/r
LS-188000
Ritonavir and Lopinavir mixture
Ritonavir-boosted lopinavir
SCHEMBL1506739
Tentative approvals for LOPINAVIR; RITONAVIR
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial200MG; 50MGTABLET; ORAL
➤ Try a Free Trial➤ Try a Free Trial200MG; 50MGTABLET; ORAL
➤ Try a Free Trial➤ Try a Free Trial200MG; 50MGTABLET; ORAL

US Patents and Regulatory Information for lopinavir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lannett Co Inc LOPINAVIR AND RITONAVIR lopinavir; ritonavir SOLUTION;ORAL 207407-001 Dec 27, 2016 AA RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for lopinavir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for lopinavir; ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,981,911 Pharmaceutical formulations ➤ Try a Free Trial
8,895,051 Flavoring systems for pharmaceutical compositions and methods of making such compositions ➤ Try a Free Trial
6,894,171 Polymorph of a pharmaceutical ➤ Try a Free Trial
7,183,416 Polymorph of a pharmaceutical ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for lopinavir; ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/044 United Kingdom ➤ Try a Free Trial PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
00060 Netherlands ➤ Try a Free Trial PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Deloitte
Farmers Insurance
QuintilesIMS
Chinese Patent Office
Dow
Julphar
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.